To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: Male

Summary

To evaluate the hormonal response to low blood sugar after a single oral dose of AZD1656 suspension.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Healthy male volunteers.

• Clinically normal physical findings (incl. Electrocardiogram (ECG)) and laboratory values as judged by the investigator.

• Have a body mass index (BMI) ≥19 and ≤30

Exclusion Criteria:

• Clinically significant illness or clinically relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the investigational product

• Intake of any prescribed medicine and OTC drugs (including herbals, vitamins and minerals), except for occasional paracetamol or nasal spray for nasal congestion, within two weeks before the first administration of the investigational product.

• Daily use of nicotine containing substances.